Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study

Evaluation of the safety of PD‐1/PD‐L1 inhibitors for immunotherapy in patients with malignant tumors after COVID‐19 infection: A single‐center cohort study

Abstract Introduction An increasing body of evidence suggests a close association between COVID‐19 infection and the safety of PD‐1/PD‐L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory. Material and Methods We...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kaili Liao, Jinting Cheng, Yujie Hu, Beining Zhang, Peng Huang, Jie Liu, Wenyige Zhang, Huan Hu, Xinyi Bai, Yihui Qian, Daixin Guo, Kun Ai, Yuchen Zhu, Long Huang
Format:	Article
Language:	English
Published:	Wiley 2024-10-01
Series:	Cancer Medicine
Subjects:	cancer COVID‐19 infection immune‐related adverse events PD‐1/PD‐L1 inhibitor propensity score matching
Online Access:	https://doi.org/10.1002/cam4.70202
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01)

Theoretical investigation on PD-L1-In-1 for cancer immunotherapy via density functional theory
by: Bijay Sijapati Magar, et al.
Published: (2025-08-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

The PD-1/PD-L1 pathway and Epstein–Barr virus
by: Hui Wang, et al.
Published: (2025-06-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

Dissecting the link between PD-1/PD-L1-based immunotherapy and cancer pain: mechanisms, research implications, and artificial intelligence perspectives
by: Marco Cascella, et al.
Published: (2024-12-01)

Effect of Astragalus polysaccharide combined with Ginsenoside Rg3 on PD-1/PD-L1 in colon cancer
by: Wang Ya’nan, et al.
Published: (2024-02-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: a retrospective study
by: Wentong Liu, et al.
Published: (2025-08-01)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024-12-01)

Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical evolution of patients with head and neck cutaneous squamous cell carcinoma?
by: Gustavo Nunes Bento, et al.
Published: (2025-09-01)

Methionine restriction promotes the polarization of macrophages towards M1 and the immunotherapy effect of PD-L1/PD-1 blockades by inhibiting the secretion of MIF by gastric carcinoma cells
by: Lin Xin, et al.
Published: (2025-01-01)

PD-1/PD-L1 and coronary heart disease: a mendelian randomization study
by: Liangjia Zeng, et al.
Published: (2024-10-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients
by: Ugur Calis, et al.
Published: (2025-01-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis
by: Deping Luo, et al.
Published: (2025-03-01)

Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy
by: Ge Y, et al.
Published: (2025-02-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-06-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis
by: Chao Song, et al.
Published: (2025-05-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)